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Abstract
Introduction: The 30-day case-fatality rate after acute myocardial infarction (MI) for rheumatoid arthritis (RA)
patients is twice that of the general population. This study compared the frequency and timeliness of early
reperfusion therapy and treatment with secondary prevention medications after acute MI in RA patients and
controls.
Methods: We performed a structured medical chart review of RA patients and matched controls who had been
admitted with acute MI to one of three hospitals in Victoria, Australia, between 1995 and 2005. The administration
and timing of acute reperfusion therapy and in-hospital treatment with secondary prevention medications were
compared between the two groups. Acute reperfusion was defined as thrombolysis or percutaneous coronary
intervention (PCI) within 12 hours of the first symptom of MI.
Results: The medical charts of 90 RA patients and 90 matched controls were reviewed. The RA patients were
significantly less likely to receive acute reperfusion compared with the controls (16% versus 37%: odds ratio (OR),
0.27; 95% confidence interval (CI), 0.10 to 0.64)), and this difference persisted after adjusting for type of MI, clinical
setting of MI, and prior MI (OR, 0.2; 95% CI, 0.05 to 0.6). The RA patients also received less-frequent in-hospital
treatment with beta blockers (71% versus 83%; OR, 0.42; 95% CI, 0.18 to 0.96) and lipid-lowering agents (40% versus
70%; OR, 0.21; 95% CI, 0.09 to 0.46).
Conclusions: RA patients who experience acute MI receive acute reperfusion and secondary prevention
medications less frequently than do controls. This may contribute to higher case-fatality rates after MI in RA
patients.
Introduction
Rheumatoid arthritis (RA) is a chronic, systemic inflam-
matory disease that manifests primarily as inflammation
in synovial joints. It is now widely recognized that RA
patients also experience excess cardiovascular morbidity
and mortality compared with the general population [1].
Not only do RA patients have an increased incidence of
cardiovascular events, such as acute myocardial infarc-
tion (MI) [2-7], but they also have an increased case-
f a t a l i t yr a t ea f t e ra c u t eM Ic o m p a r e dw i t ht h eg e n e r a l
population [8-10]. For example, in our previous study of
almost 30,000 individuals who had experienced a first
acute MI, the adjusted odds ratio (OR) for 30-day mor-
tality in RA patients versus controls was 1.9 (95% confi-
dence interval (CI), 1.3 to 2.7) [8].
The reasons for a higher case-fatality rate after MI in
RA patients are not known. Possible explanations
include delays in seeking medical attention or in diagno-
sis, detrimental effects of systemic inflammation or con-
current RA medications or both, different patterns of
coronary artery disease in RA patients, or differential
treatment after the acute cardiac event. In our
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onary intervention (PCI) was performed half as often in
RA patients as in the controls (adjusted OR, 0.5; 95%
CI, 0.3 to 0.8), which suggests that RA patients receive
differential treatment [8]. However, in that study, we
had no data on the frequency of administration of
thrombolysis, the reason(s) that PCI was less frequently
used in the RA patients, nor the frequency of treatment
with secondary prevention pharmacotherapy after MI.
T h ea i mo ft h ep r e s e n ts t u d yw a st oi n v e s t i g a t e
whether the treatment received by RA patients after an
acute MI is different from that received by the general
population, and if so, why. We addressed this by com-
paring the frequency of acute reperfusion therapy (PCI
or thrombolysis) and treatment with secondary preven-
tion pharmacotherapy in RA patients compared with
controls after acute MI.
Materials and methods
We performed a structured medical chart review of RA
patients and matched controls who had been admitted
with acute MI to one of three hospitals in Victoria, Aus-
tralia (The Royal Melbourne Hospital, The Alfred Hos-
pital, and Epworth Hospital) between 1995 and 2005.
The Royal Melbourne and Alfred hospitals are major
metropolitan public hospitals, and the Epworth is a
major metropolitan private hospital. The study was
approved by the ethics committee of each of the partici-
pating hospitals. Informed consent from patients was
not required by the ethics committees, as the study
involved chart review only.
Identification of study population
We obtained from each hospital a de-identified list of all
patients with a discharge diagnosis of acute MI (Interna-
tional Classification of Diseases (ICD) 9-CM (Aust v2)
code 410.xx or ICD 10-AM code I21.xx) between 1 July
1995 and 30 June 2005 (hereafter referred to as “MI
admission”). The 15,278 individuals had received a dis-
charge diagnosis of acute MI from one of the three par-
ticipating hospitals between 1 July 1995 and 30 June
2005. We identified RA patients as those who had also
received a discharge diagnosis code for RA (ICD 9-CM
(Aust v2) code 714.xx or ICD 10-AM codes M05.xx,
M06.xx, or M08.0) during the MI admission or any pre-
vious admission. Within the cohort of 15,278 acute MI
cases, 133 individuals had also received a discharge diag-
nosis of RA and were classified as RA cases. The
remaining 15,145 patients were classified as non-RA.
The medical charts of the 133 RA patients were
requested for formal review. Forty-three (32%) of the
RA cases were not able to be included in the study: nine
(7%) of the charts were unavailable or incomplete, 20
( 1 6 % )d i dn o tm e e tc r i t e r i a for RA, and 14 (11%) did
not meet criteria for definite MI. The remaining 90 RA
patients (50, Alfred Hospital; 25, Royal Melbourne Hos-
pital; 15, Epworth Hospital) were included in the study.
The chart review of the control patients was performed
in a similar manner. Thirty-four (38%) of the 90
matched controls initially selected were not able to be
included in the study: 18 (20%) charts were unavailable
or incomplete, and 16 (18%) patients did not meet cri-
teria for definite MI. In these instances, a second
matched control was selected from the de-identified list.
Definitions used for the chart review
The diagnosis of RA was considered to be correct if a
doctor had documented the diagnosis of RA in the chart
during the MI admission or during any previous hospital
encounter. We chose this definition of RA because com-
prehensive documentation of RA diagnostic criteria is
frequently omitted in hospital medical notes, especially
if the patient has been admitted with a nonrheumatolo-
gic medical condition (such as MI). We predicted that
the use of more-stringent diagnostic criteria would
result in the exclusion of many patients who truly had
RA, because of an absence of detailed medical notes,
rather than any doubt about the diagnosis. For each
patient who met our definition of RA, we recorded addi-
tional information supporting the diagnosis of RA,
including whether the patient fulfilled American College
of Rheumatology (ACR) diagnostic criteria [11] or was
being treated with disease-modifying antirheumatic drug
(DMARD) therapy or both.
Myocardial infarction was defined according to the
2003 American Heart Association Scientific Statement
[12] and was categorized as either ST-elevation MI
(STEMI) or non-STEMI. We included only patients who
were classified as “definite” MI. We defined “acute
reperfusion” as the administration of thrombolysis or
PCI within 12 hours of the first symptom of MI. Preex-
isting cardiovascular risk factors and comorbidities were
recorded if they were documented in the medical chart
or if the patient was receiving treatment for the condi-
tion during the MI admission. The documentation of a
medical condition in the chart was largely due to patient
self-report; however, results of prior investigations (for
example, angiography, surgical procedures) or prior hos-
pital admissions or both were also taken into considera-
tion. Medications that we considered indicative of a
medical condition included lipid-lowering agents (for
hypercholesterolemia) and oral hypoglycemic agents or
insulin (for diabetes mellitus).
Chart-review procedure
The RA patients’ charts were first reviewed for confir-
mation of the diagnoses of RA and MI, as defined ear-
lier. If the diagnoses of RA and MI were not confirmed,
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noses of RA and MI were confirmed, the patient was
included in the study, and a full review of the chart was
performed, as described later. For each RA patient in
the study, a non-RA control matched for age at time of
MI (±1 year), gender, treating hospital, and year of MI
(±1 year) was selected from the de-identified list. The
control patients’ charts were reviewed for a diagnosis of
MI, as defined earlier. If the diagnosis of MI was not
confirmed, the patient was excluded from the study, and
another control was selected from the de-identified list.
If the diagnosis of MI was confirmed, the patient was
included in the study, and a full review of the chart was
performed.
Chart abstraction and data collection were performed by
a trained research assistant using a structured audit form.
The accuracy of the chart abstraction was verified by inde-
pendent audit of 5% of the charts by a second investigator
(SV). The RA patients’ charts were reviewed for RA-
related characteristics, including ACR diagnostic criteria
[11], disease duration, extraarticular disease, and DMARD
treatment in the past and at the time of the MI admission.
The charts of all patients (RA and non-RA) were reviewed
for: confirmation of MI and type of MI, conventional car-
diovascular risk factors and other comorbidities (including
prior MI), medications taken at time of MI admission,
administration and timing of reperfusion therapy (throm-
bolysis or PCI), and post-MI events such as in-hospital
death and coronary artery bypass graft surgery. The clini-
cal setting of the MI was classified into one of three cate-
gories: (a) “community based,” the MI occurred outside a
hospital with no acute medical illness immediately preced-
ing it; (b) “after medical illness,” the patient was already an
inpatient for a medical illness and experienced the MI as a
complication during that hospital admission; or (c) “after
surgical event,” the patient was already an inpatient and
had undergone a surgical procedure and experienced the
MI as a complication during that hospital admission.
Urgent reperfusion is not necessarily indicated in all cases
of MI; however, in the event of STEMI, early thrombolysis
or PCI is considered the standard of care [13]. In those
patients who experienced an STEMI and did not receive
acute reperfusion, the reason for lack of acute reperfusion
was determined from extensive review of the chart and
was categorized as either (a) delayed diagnosis due to late
presentation; (b) delayed diagnosis due to diagnostic
uncertainty; (c) presence of a contraindication; or (d)
unable to ascertain the reason. We also recorded whether
treatment with secondary prevention medications (specifi-
cally aspirin, beta blockers, angiotensin-converting enzyme
(ACE) inhibitors, lipid-lowering agents, or a combination
of these) was commenced during the hospital stay for each
patient. If a patient had an allergy or other condition pre-
cluding the use of these medications, or if the patient was
previously taking the medication and it was continued
during the MI admission, the treatment was considered to
have been provided.
Statistical analysis
The primary end point was the proportion of patients
who received acute reperfusion after MI. In performing
our sample-size calculation, we used data from our pre-
vious study, in which we found that RA patients were
treated with PCI half as often as non-RA patients.
Assuming acute reperfusion rates of 50% in the control
patients and 25% in the RA patients, with power = 0.9
and alpha = 0.05, we calculated that a sample of 85 par-
ticipants per group would be required. Descriptive data
were summarized by using population means and stan-
dard deviation or percentages, as appropriate. Baseline
characteristics and treatment with secondary prevention
medications of the RA and control patients were com-
pared by using the McNemar test for categoric variables
and the paired t test for continuous variables. Treatment
with cardiac interventions such as acute reperfusion,
thrombolysis, and PCI in the RA and control patients
was compared with the McNemar test (unadjusted ana-
lysis) and with conditional logistic regression adjusted
for clinical setting of MI, type of MI, and prior MI. Our
study covered a 10-year period during which the treat-
ment of acute coronary syndromes evolved considerably.
We therefore performed a post hoc analysis in which we
compared treatment with acute reperfusion and second-
ary prevention pharmacotherapy between RA and con-
trols over three time periods: prior to 1999, 1999 to
2002 inclusive, and after 2002. Analyses were performed
with the use of Stata software version 10.0 (StataCorp,
College Station, TX, USA).
Results
Demographic details, cardiovascular risk factors, and
other comorbidities of the RA and control patients are
shown (Table 1). Fifty-five (61%) of the patients were
women, with a mean age of 71 ± 10 years. The RA
group had longstanding disease (mean disease duration,
20 ± 13 years) and were taking an average of 1.4
DMARDs at the time of the MI. Only one RA patient
was using a biologic DMARD. Forty-nine (54%) of the
RA patients had sufficient documentation in the chart
to confirm the diagnosis of RA according to ACR cri-
teria. Seventy-eight (87%) of the RA patients either ful-
filled ACR criteria or were taking one or more
DMARDs at the time of the MI.
No difference was found in the prevalence of tradi-
tional cardiovascular risk factors between the two groups,
with the exception of hyperlipidemia, which was less pre-
valent in the RA group than in the control group (24%
versus 42%; P = 0.02). The prevalence of ischemic heart
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in the two groups; however, peripheral vascular disease
was more common in the RA group than in the control
group (21% versus 6%; P = 0.002).
Reperfusion therapy
Table 2 shows the treatment received by the RA and
control patients after acute MI. No difference was noted
between hospitals in the proportion of patients who
received acute reperfusion (data not shown), so we pre-
sent combined hospital data. In the unadjusted analysis,
the RA patients were significantly less likely to receive
acute reperfusion compared with the controls (16% ver-
s u s3 7 % ,r e s p e c t i v e l y ;O R ,0 . 2 7 ;9 5 %C I ,0 . 1 0t o0 . 6 4 ) .
Thrombolysis was performed in 9% of the RA patients
compared with 24% of the controls (OR, 0.3; 95% CI,
0.1 to 0.77); PCI was performed in 11% of the RA
patients compared with 33% of the controls (OR, 0.2;
95% CI, 0.06 to 0.53); and coronary angiography was
performed in 43% of the RA patients compared with
58% of the controls (OR, 0.41; 95% CI, 0.16 to 0.92).
Coronary artery bypass surgery was performed more fre-
quently in the controls; however, this variance did not
reach statistical significance.
The presence of a medical or surgical illness immedi-
ately before the MI was substantially more common in
the RA patients than in the controls (31% versus 16%,
r e s p e c t i v e l y :O R ,2 . 5 ;9 5 %C I ,1 . 2t o5 . 5 ) .T h ec l i n i c a l
setting of the MI, the type of MI, and the past history of
MI could potentially have affected the likelihood that
acute reperfusion was provided. Therefore, we per-
formed an analysis by using conditional logistic regres-
sion, with adjustment for these variables (Table 2). In
the adjusted analysis, RA patients remained significantly
less likely to be treated with acute reperfusion, thrombo-
lysis, and PCI, suggesting that acute concurrent condi-
tions or prior MI or both were not responsible for the
observed differential treatment of RA patients.
We also performed an analysis restricted to the sub-
group of RA patients who fulfilled ACR criteria (n = 49)
along with their matched controls. Compared with the
controls, the ACR-defined RA patients were significantly
less likely to receive acute reperfusion (OR, 0.31; 95%
CI, 0.11 to 0.85), thrombolysis (OR, 0.14; 95% CI, 0.03
to 0.62), and PCI (OR, 0.27; 95% CI, 0.07 to 0.98). Cor-
onary angiography and coronary artery bypass surgery
were performed more frequently in the controls; how-
ever, this variance did not reach statistical significance.
Table 1 Demographic and clinical features of the RA and
control patients admitted to participating Victorian
hospitals with acute MI between 1995 and 2005
RA (n = 90) Controls
(n = 90)
Female, n (%) 55 (61) 55 (61)
Age in years, mean (SD) 71 (10) 71 (10)
RA disease duration in years, mean (SD) 20 (13) -
Seropositive, n (%)
a 35 (78) -
No. of DMARDs, mean (SD) 1.4 (1.1) -
Taking NSAID at time of MI, n (%) 21 (23) 6 (7)
b
Preexisting comorbidities:
Ischemic heart disease, n (%) 31 (34) 33 (37)
Prior MI, n (%) 10 (11) 11 (12)
Cerebrovascular disease, n (%) 8 (9) 9 (10)
Peripheral vascular disease, n (%) 19 (21) 5 (6)
b
IDDM, n (%) 3 (3) 1 (1)
NIDDM, n (%) 22 (24) 27 (30)
Hypertension, n (%) 52 (58) 56 (62)
Hypercholesterolemia, n (%) 22 (24) 38 (42)
b
Current smoker, n (%) 14 (15) 16 (18)
Previous smoker, n (%) 41 (46) 27 (30)
Congestive cardiac failure, n (%) 15 (17) 11 (12)
Chronic lung disease, n (%) 28 (31) 16 (18)
Chronic renal impairment, n (%) 15 (17) 8 (9)
Chronic lung disease: asthma, chronic obstructive airways disease, and
pulmonary fibrosis; DMARD, disease-modifying antirheumatic drug; IDDM,
insulin-dependent diabetes mellitus; MI, myocardial infarction; NIDDM, non-
insulin-dependent diabetes mellitus; NSAID, nonsteroidal antiinflammatory
drug; RA, rheumatoid arthritis.
aData available for 45 of 90 RA patients.
bP value < 0.05.
Table 2 Treatment received by RA and control patients after myocardial infarction
RA (n = 90) Controls (n = 90)
n % n % Unadjusted OR
a
(95% CI)
Adjusted OR
b
(95% CI)
Acute reperfusion
c 14 16 33 37 0.27 (0.10-0.64) 0.21 (0.07-0.62)
Thrombolysis 8 9 22 24 0.30 (0.10-0.77) 0.33 (0.11-0.96)
PCI 10 11 30 33 0.20 (0.06-0.53) 0.23 (0.09-0.63)
PCA 39 43 52 58 0.41 (0.16-0.92) 0.54 (0.23-1.25)
CABGS 11 12 17 19 0.57 (0.21-1.46) 0.67 (0.27-1.65)
CABGS, coronary artery bypass graft surgery; CI, confidence interval; OR, odds ratio; PCA, percutaneous coronary angiography; PCI, percutaneous coronary
intervention (angioplasty ± insertion of stent); RA, rheumatoid arthritis.
aMcNemar c
2 test.
bConditional logistic regression, adjusting for type of MI (STEMI or
NSTEMI), presence of prior MI, and clinical setting of MI.
cAcute reperfusion defined as the administration of thrombolysis or PCI within 12 hours of the first
symptom of MI.
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therapy
From our total study cohort of 180 patients, 29 of the RA
patients and 39 of the controls were diagnosed with
STEMI. Acute reperfusion was administered in 48% of the
RA-STEMI patients versus 74% of the control-STEMI
patients (P = 0.027 with the c
2 test). In those STEMI
patients who did not receive acute reperfusion (n = 25),
delayed diagnosis of MI was the most common reason for
failure to provide acute reperfusion: six (40%) of RA
patients and five (50%) of controls. It was previously
demonstrated that RA patients experience a higher rate of
silent MI than does the general population, and this may
also contribute to a delay in presentation to hospital [9,14].
In our study, 39% of the RA patients did not experience
chest pain during the MI compared with 22% of the con-
trol patients (OR, 0.5; 95% CI, 0.3 to 0.9). A contraindica-
tion to acute reperfusion was present in five (33%) of the
RA patients, whereas none of the controls had a contrain-
dication. In four (27%) of the RA patients and five (50%) of
the controls, no clear reason was found for not providing
acute reperfusion after careful review of the medical chart.
The numbers were too small in this subgroup of 25
patients to make any meaningful statistical comparisons;
however, the difference in the prevalence of contraindi-
cation to acute reperfusion between the RA and control
groups was of interest. Five RA patients had a contrain-
dication to acute reperfusion; one had peptic ulcer dis-
ease (bleeding risk), one had a recent intracerebral
bleed, and three patients had undergone major surgery
in the previous 5 days. This was consistent with our
finding that an antecedent medical illness or surgical
event was more common in the RA subjects.
Secondary prevention therapy
Table 3 shows the number of RA and control patients
who received treatment with selected secondary preven-
tion medications. The RA patients received less-frequent
treatment with beta blockers (71% versus 83%: OR, 0.42
(95% CI, 0.18 to 0.96)) and lipid-lowering agents (40%
versus 70%: OR, 0.21 (95% CI, 0.09 to 0.46)).
Ten of the RA patients and 11 of the controls had
experienced MI before the study “MI admission.” Table
4 shows the numbers of these patients who were already
taking selected secondary prevention medications at the
time of the study MI. The RA patients had lower rates
of treatment with aspirin, beta blockers, and lipid-lower-
ing agents at the time of their recurrent MI. These data
mirror our findings in the analysis of the entire cohort
and serve to validate the results of the present study.
Changes in post-MI care over time
Table 5 shows the frequency of selected post-MI treat-
ments in RA and control patients for three time periods
within our study period: prior to 1999, 1999 through
2002, inclusive, and 2003 and onward. For virtually all
interventions, in each of the time periods, the RA
patients received less-frequent treatment than did the
controls. Within the subgroup of STEMI patients, a sug-
gestion of higher rates of acute reperfusion was found in
the most recent time period (small numbers limit this
result); however, in all time periods, the RA patients
received less-frequent acute reperfusion than did the
controls. Treatment with lipid-lowering agents increased
progressively over time for all patients; however, in each
time period, RA patients again received less-frequent
treatment with lipid-lowering agents than did controls.
Discussion
We previously demonstrated an almost twofold increase
in the 30-day case-fatality rate after MI in RA patients;
however, the reason(s) for this increased mortality were
not clear. In the present study, we investigated whether
this difference in case fatality might be partially
explained by RA patients receiving different rates of
treatment with acute reperfusion or secondary preven-
tion medications or both after the acute event.
We found that RA patients were substantially less
likely to be treated with acute reperfusion after MI, and
that this difference persisted after adjusting for type of
MI, clinical setting of the MI, and prior MI (OR, 0.2;
95% CI, 0.05 to 0.6). We attempted to determine the
explanation for this discrepancy by examining the charts
Table 3 In-hospital treatment with secondary prevention
medications received by RA and control patients after
myocardial infarction
RA
(n = 90)
Controls
(n = 90)
n % n %O R
a (95% CI)
Aspirin 85 94 89 99 0.20 (0.02-1.71)
Beta blockers 64 71 75 83 0.42 (0.18-0.96)
ACE inhibitors 61 68 57 63 1.18 (0.67-2.08)
Lipid-lowering agents 36 40 63 70 0.21 (0.09-0.46)
ACE, angiotensin-converting enzyme; CI, confidence interval; OR, odds ratio;
RA, rheumatoid arthritis.
aMcNemar c
2 test. Acute reperfusion is defined as
the administration of thrombolysis or PCI within 12 hours of the first
symptom of MI.
Table 4 Use of secondary prevention medications at the
time of “MI admission” in RA and control patients with a
prior history of MI
RA (n = 10) Controls (n = 11)
Aspirin, n (%) 3 (30) 6 (55)
Beta blocker, n (%) 1 (10) 4 (36)
ACE inhibitor, n (%) 3 (30) 3 (27)
Lipid-lowering agent, n (%) 2 (20) 5 (45)
ACE, angiotensin-converting enzyme; RA, rheumatoid arthritis.
Van Doornum et al. Arthritis Research & Therapy 2010, 12:R183
http://arthritis-research.com/content/12/5/R183
Page 5 of 8for the reasons for failure to provide acute reperfusion
in STEMI patients. Diagnostic delay was the reason for
failure to treat in 11 (44%) of the 25 STEMI patients
who did not receive acute reperfusion. Delayed presen-
tation was more common in the RA patients, whereas a
delay in confirming the diagnosis (after presentation)
was more common in the controls. No identifiable rea-
son was found for failure to treat in nine (36%) of the
25 STEMI patients who did not receive acute
reperfusion.
Within the group of STEMI patients who did not
receive acute reperfusion, the most obvious difference
between the RA and control patients was in the fre-
quency of contraindication to acute reperfusion. In one
third of the RA STEMI patients who did not receive
acute reperfusion, the reason recorded was the presence
of a contraindication–in most cases, a preceding acute
medical or surgical event. Similarly, in the overall cohort
of 180 patients, a preceding medical illness or surgical
event was more common in the RA patients than in the
controls (31% versus 16%, respectively). Lichtman et al.
[15] demonstrated in non-RA patients that the presence
of a concurrent acute, severe, noncardiac condition at
the time of MI was associated with lower rates of treat-
ment with reperfusion therapy (even among patients
who were “ideal candidates”)a n dw a sa s s o c i a t e dw i t h
higher in-hospital mortality. Although the higher rate of
concomitant illness in the RA patients in our study may
have contributed to lower rates of acute reperfusion and
secondary prevention therapy in this group, it is impor-
tant to emphasize that the discrepancies persisted even
with analysis adjusted for the clinical setting of MI.
Secondary prevention with medications such as
aspirin, beta blockers, angiotensin-converting enzyme
(ACE) inhibitors, and lipid-lowering agents is an impor-
tant component of post-MI care [13]. A major finding
of our study was that RA patients received lower rates
of treatment with secondary prevention medications
after MI. This was evident both in the total study cohort
and in those patients who had experienced MI before
the “MI admission.” In the decade covered by our study,
RA patients were 58% less likely to receive treatment
with beta blockers and 79% less likely to receive treat-
ment with lipid-lowering agents. Given that prompt
implementation of reperfusion therapy and post-MI
treatment with beta blockers and lipid-lowering agents
are major determinants of outcome after acute MI, this
lower rate of treatment after MI may help to explain
why case-fatality rates are higher in RA than in the gen-
eral population. It is unclear why RA patients were
Table 5 Post-MI treatment in RA and control patients: comparison of three time periods
Prior to 1999 1999 to 2002 inclusive 2003 onward
Acute reperfusion (all patients)
RA patients, n (%) 6/16 (38%) 4/38 (10%)* 4/28 (12%)
Controls, n (%) 10/19 (53%) 17/41 (41%) 6/30 (20%)
Acute reperfusion (STEMI patients)
RA patients, n (%) 6/10 (60%) 4/13 (31%)* 4/6 (67%)
Controls, n (%) 9/12 (75%) 14/20 (70%) 6/7 (86%)
Thrombolysis
RA patients, n (%) 3/16 (19%) 3/42 (7%)* 2/32 (6%)
Controls, n (%) 8/19 (42%) 12/41 (29%) 2/30 (7%)
Percutaneous coronary intervention
RA patients, n (%) 4/16 (25%) 3/42 (7%)* 3/32 (9%)*
Controls, n (%) 3/19 (16%) 15/41 (36%) 12/30 (40%)
Aspirin
RA patients, n (%) 14/16 (88%) 41/42 (98%) 30/32 (94%)
Controls, n (%) 19/19 (100%) 41/41 (100%) 29/30 (97%)
Beta blockers
RA patients, n (%) 8/16 (50%) 32/42 (76%) 24/32 (75%)
Controls, n (%) 15/19 (79%) 32/41 (78%) 28/30 (93%)
ACE inhibitors
RA patients, n (%) 8/16 (50%) 29/42 (69%) 24/32 (75%)
Controls, n (%) 14/19 (74%) 24/41 (58%) 19/30 (63%)
Lipid-lowering agents
RA patients, n (%) 0/16 (0)* 16/42 (38%)* 20/32 (62%)
Controls, n (%) 7/19 (37%) 31/41 (76%) 25/30 (83%)
ACE, angiotensin-converting enzyme; MI, myocardial infarction; RA, rheumatoid arthritis; STEMI, ST-elevation myocardial infarction. *P < 0.05 for the comparison
with control patients.
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discrepancy is not explained by differences in the preva-
lence of contraindication or serious comorbidity,
because in these instances, the treatment was considered
to have been provided. It is possible that concerns
regarding toxicity, such as myositis, or exacerbating
polypharmacy in the RA patients led to reluctance to
prescribe additional medications.
O u rs t u d yc o v e r e da1 0 - y e a rp e r i o df r o m1 9 9 5t o
2005, during which time the treatment of acute coron-
ary syndromes evolved considerably. In the late 1990s
and early 2000s, a significant shift occurred toward
more-aggressive use of reperfusion therapy and routine
prescription of lipid-lowering agents for secondary pre-
vention of acute coronary syndromes (regardless of lipid
levels) after publication of evidence supporting this
practice [16-19]. Our study design, in which patients are
matched for year of MI, compensates for changing prac-
tice over time. Having demonstrated lower rates of
acute reperfusion and secondary prevention treatment
in the RA patients, we were interested to explore the
pattern of treatment over time. We found that for vir-
tually all interventions, the RA patients received less-
frequent treatment than did the controls, and that the
differences persisted throughout all time periods. This
suggests that the relative undertreatment of RA patients
who experience MI is ongoing, despite the considerable
literature relating to cardiovascular risk in RA.
This study has a number of potential limitations. We
sampled only a small proportion of the RA patients in
Victoria who experienced a hospital admission for MI
over the 10-year study period. During the case-selection
process, RA patients could have been missed if they
were not coded as having RA during their hospital
admission(s). The Victorian hospital coding standard
requires that concurrent diagnoses that receive treat-
ment during hospitalization be coded. Between 12 and
40 concurrent diagnoses are coded, depending on the
year. It would therefore be expected that an RA patient
whose medications were continued in hospital during
the MI admission would be coded as RA, regardless of
whether they had ever been admitted for RA. Misclassi-
f i c a t i o nw o u l db em o r el i k e l yf o rp a t i e n t sw i t hm i l dR A
(not receiving any treatment) and may mean that only
RA patients with more-severe disease were included in
the study. Increased ascertainment of RA status in
patients who experienced MI in the context of a rheu-
matoid-related admission is also possible. Such misclas-
sification could mean that our sample is not
representative of the full spectrum of RA patients and
that our results may be relevant only to patients with
more-severe disease. Our study included only metropoli-
tan hospitals, so may not reflect practice in rural loca-
tions. Diagnosis of cardiovascular risk factors and other
comorbidities was based on patient self-report and
therefore may be inaccurate; however, the degree of
i n a c c u r a c yi su n l i k e l yt ob ed i f f e r e n tb e t w e e nt h eR A
and control groups. Furthermore, the presence or
absence of the listed cardiovascular risk factors and
comorbidities are not determinants of whether to pro-
vide acute reperfusion in the event of MI and thus do
not act as confounders in the comparison. In one third
of STEMI patients, no reason was ascertainable for not
providing acute reperfusion treatment. It is possible that
valid reasons existed for some or all of these episodes of
“failure to treat,” b u tt h a tt h i sr a t i o n a l ew a sn o td o c u -
mented and therefore not apparent to the investigators.
Again, it is unlikely that documentation omissions were
distributed differently between RA and non-RA cases;
therefore, bias is unlikely.
Conclusions
In this retrospective study of 90 RA patients and 90
matched controls with acute MI, we found that the RA
group received acute reperfusion and secondary preven-
tion medications less frequently than did the control
group. These discrepancies persisted despite adjustment
for relevant clinical factors and were present within all
time periods within the study duration. RA patients
should be considered a high-risk group after MI and
considered for acute reperfusion therapy along the same
lines as the general population, in line with current best
practice. In the absence of contraindications, RA
patients should also receive recommended secondary
prevention therapy after MI, in keeping with evidence-
based guidelines for the general population.
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